TY - JOUR
T1 - The diagnosis and management of portal hypertension in cirrhosis
T2 - the Gastroenterological society of Australia consensus
AU - Majumdar, Avik
AU - Holmes, Jacinta
AU - Roberts, Stuart K.
AU - Bhat, Purnima
AU - Mitchell, Tim
AU - Ramachandran, Jeyamani
AU - O’Beirne, James
AU - Walker, Sarah
AU - Sawhney, Rohit
AU - Jagarlamudi, Nishita
AU - Jacob, Rachael
AU - Gill, Madeleine
AU - Thomas, James A.
AU - Bloom, Stephen
AU - Gracen, Lucy
AU - Kemp, William
AU - Raj, Ashok
AU - Thompson, Alexander J.
AU - Romero, Sarah
AU - Doyle, Adam
AU - Maher, Adrian
AU - Pow, Richard
AU - Robertson, Marcus
AU - Tiwari, Neha
AU - Tibballs, Jonathan
AU - Lubel, John
AU - Popuri, Radha
AU - Testro, Adam
AU - Valliani, Talal
AU - Waller, Karen
AU - Chapman, Brooke
AU - Gupta, Rohit
AU - Hey, Penelope
AU - Keating, Shelley
AU - Sinclair, Marie
AU - Janko, Natasha
AU - Koshy, Anoop
AU - Majeed, Ammar
AU - Mohammadi, Fadak
AU - Fergusson, James
AU - Furtado, Ruelan
AU - MacQuillan, Gerry
AU - Muller, Kate
AU - Santhakumar, Cositha
AU - Ahlenstiel, Golo
AU - Strasser, Simone I.
PY - 2026/4
Y1 - 2026/4
N2 - Background: – In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50–59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis was developed by the Gastroenterological Society of Australia (GESA), the peak national organization for health care professionals and researchers working in gastroenterology and hepatology, to provide contemporary, evidence-based clinical guidelines. A summary of its recommendations is presented here. Methods: – The consensus statement was developed in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument and the 2016 National Health and Medical Research Council Standards for Guidelines. A panel of 46 health care professionals with expertise in managing portal hypertension participated in the development of the consensus statement. The consensus development conference method was used to determine consensus for each recommendation, with a hybrid face-to-face and online meeting held in Noosa, Australia, on 3 August 2024, followed by 2 online meetings. Results: – A total of 52 recommendations were approved by the consensus development group without dissent across the following domains: (1) diagnosis, risk stratification, and prevention of decompensation; (2) portal hypertension–related bleeding; (3) ascites and renal impairment; (4) hepatic encephalopathy; (5) sarcopenia, nutrition, and frailty; (6) thrombosis in cirrhosis; (7) cardiopulmonary complications; (8) surgery and portal hypertension; and (9) pregnancy and portal hypertension. Discussion: – This is the first Australian consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis. The recommendations in this summary document provide standardized clinical guidance with the goal of improving outcomes for patients with cirrhosis and portal hypertension in Australia.
AB - Background: – In Australia, chronic liver disease is now the third leading cause of premature death in people aged 50–59 years, and the fourth leading cause in all other 5-year age groups from 35 to 70 years in Australia. A consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis was developed by the Gastroenterological Society of Australia (GESA), the peak national organization for health care professionals and researchers working in gastroenterology and hepatology, to provide contemporary, evidence-based clinical guidelines. A summary of its recommendations is presented here. Methods: – The consensus statement was developed in accordance with the Appraisal of Guidelines for Research and Evaluation II instrument and the 2016 National Health and Medical Research Council Standards for Guidelines. A panel of 46 health care professionals with expertise in managing portal hypertension participated in the development of the consensus statement. The consensus development conference method was used to determine consensus for each recommendation, with a hybrid face-to-face and online meeting held in Noosa, Australia, on 3 August 2024, followed by 2 online meetings. Results: – A total of 52 recommendations were approved by the consensus development group without dissent across the following domains: (1) diagnosis, risk stratification, and prevention of decompensation; (2) portal hypertension–related bleeding; (3) ascites and renal impairment; (4) hepatic encephalopathy; (5) sarcopenia, nutrition, and frailty; (6) thrombosis in cirrhosis; (7) cardiopulmonary complications; (8) surgery and portal hypertension; and (9) pregnancy and portal hypertension. Discussion: – This is the first Australian consensus statement on the diagnosis and management of portal hypertension in patients with cirrhosis. The recommendations in this summary document provide standardized clinical guidance with the goal of improving outcomes for patients with cirrhosis and portal hypertension in Australia.
KW - advanced liver disease
KW - ascites
KW - chronic liver disease
KW - encephalopathy
KW - hepatorenal syndrome
KW - variceal bleeding
KW - varices
UR - https://www.scopus.com/pages/publications/105037364936
U2 - 10.1097/HC9.0000000000000934
DO - 10.1097/HC9.0000000000000934
M3 - Article
C2 - 41921189
AN - SCOPUS:105037364936
SN - 2471-254X
VL - 10
JO - Hepatology Communications
JF - Hepatology Communications
IS - 4
M1 - e0934
ER -